Sufentanil

Phase 3 Trial for Sublingual Sufentanil for the Treatment of Moderate-to-Severe Acute Pain

Phase 3 Trial for Sublingual Sufentanil for the Treatment of Moderate-to-Severe Acute Pain

By

ARX-04 would provide a non-invasive option for moderate-to-severe acute pain in medical settings.

Sign Up for Free e-Newsletters